Lumida
/CNMD
⌘K
Conmed Corp

Conmed Corp

CNMD
$43.20USD↓-4.02%-1.81 today

MARKET CAP

1.3B

P/E (TTM)

9.5x

FWD P/E

9.3x

DAY RANGE

$43 – $45

52W RANGE

$31
$57

AI Summary

Stalk
Buy NowMedium

CNMD remains in a Stage 2 advancing phase with a strong breakout and rising EMA support. An active Lockout Rally signals forced participation, overriding typical overbought concerns and justifying immediate buy-side engagement. Continuation participation now captures urgent repricing dynamics while relying on the EMA structure. Caution remains due to extreme overbought levels and the potential for a pullback.

  • ↑Q1 revenue of $321.3M (+2.9% YoY) and 2025 guidance of $1.35–1.378B
  • ↑AirSeal and BioBrace platforms expected to drive high single-digit to low double-digit growth
  • ↓Q1 adjusted net income $29.6M (down 8.5% YoY) highlights cost and segment exit impacts
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

ConMed Corporation (NASDAQ: CNMD) is a leading player in the medical technology sector, focusing primarily on surgical devices and equipment. The company emphasizes minimally invasive surgery and has strategically aligned itself toward growth platforms in orthopedics and surgical smoke evacuation technologies. With a commitment to innovation, ConMed has distinguished itself in high-margin segments, addressing growing markets in robotic and laparoscopic surgery while maintaining a focus on enhancing patient outcomes through its product offerings.

Bull says

  • ↑Q1 revenue of $321.3M (+2.9% YoY) and 2025 guidance of $1.35–1.378B
  • ↑AirSeal and BioBrace platforms expected to drive high single-digit to low double-digit growth
  • ↑$150M share buyback program and book-to-price 1.76 suggest undervaluation
  • ↑Legislative support in 20 states boosts demand for smoke-free OR solutions
  • ↑Record manufacturing volumes post-supply chain fixes support margin stability
  • ↑Gross margin up 80bps to 56.4%; debt down to $891.4M (leverage 3.2)

Bear says

  • ↓Q1 adjusted net income $29.6M (down 8.5% YoY) highlights cost and segment exit impacts
  • ↓Negative profitability factors press margins amid inflationary raw-material costs
  • ↓Market share losses acknowledged due to prior supply constraints and rival devices
  • ↓Dividend suspension for buybacks risks alienating income-focused investors
  • ↓Analyst forecast revisions trending lower indicate waning earnings visibility
  • ↓High sensitivity to energy costs and rising short interest signal investor caution

Investment themes with CNMD

Medical Devices↑ +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-30-2026neutral

Transcript signals

Bull points

  • We are pleased to be able to raise our organic growth expectation for 2026 to 5.0% to 6.5% from our prior range of 4.5% to 6.0%.
  • Because of our improving growth profile, despite that approximate $7 million of lower GI revenue for the year, we are raising the lower end of our reported range by $5 million and keeping the high end of the range the same.
  • We expect reported revenue in Q2 to be between $336 million and $340 million.

Bear points

  • Total sales for the quarter were $317 million, a decrease of 1.3% compared to the prior year quarter.
  • From an earnings perspective, excluding special items that affected comparability, our adjusted net income of $27.1 million decreased 8.5% year over year, and our adjusted diluted net earnings per share of 89 cents decreased 6.3% year over year.
  • We are seeing some pressure on some commodity products like oil, gold. They're affecting our cost of goods sold, but we're working hard with our vendors and our partners and our supply chain to mitigate as much as we can there.
Read full transcript analysis ›